2′,2′-difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA)

Stem Cells

Volumn 14, Issue 3, 1996, Pages 351-362

  Gruber, Johann ^a   Geisen, Françoise ^a   Sgonc, Roswitha ^b   Egle, Alexander ^a   Villunger, Andreas ^a   Boeck, Guenther ^b   Konwalinka, Günther ^a   Greil, Richard ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b Institute for General and Experimental Pathology   (Austria)

Author keywords

2 chlorodeoxyadenosine; Apoptosis; CFU GM colony growth; Gemcitabine; Multiple myeloma; Steroid resistance

Indexed keywords

CLADRIBINE; CYTOTOXIC AGENT; DEXAMETHASONE; GEMCITABINE; STEROID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MULTIPLE MYELOMA; MYELOMA CELL;

2-CHLOROADENOSINE; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BIOTIN; DEOXYADENOSINES; DEOXYCYTIDINE; DEOXYURACIL NUCLEOTIDES; DEXAMETHASONE; DNA DAMAGE; DRUG RESISTANCE; GLUCOCORTICOIDS; HEMATOPOIETIC STEM CELLS; HUMANS; LYMPHOMA, LYMPHOBLASTIC; MULTIPLE MYELOMA; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; STEROIDS; TUMOR CELLS, CULTURED;

EID: 0029898420     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.140351     Document Type: Article

References (41)

1. Alexanian R, Dimopoulos MA, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992;80:887-890.
2. Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993;341:1251-1254.
3. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-1356.
4. Fernand JP, Levy Y, Gerota J et al. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood 1989;73:20-23.
5. Altai M, Harousseau JL, Stoppa AM et al. High-dose chemotherapy in multiple myeloma: a prospective randomized study of the "Intergroupe Français du Myelome" (IFM). Vth International Workshop on Multiple Myeloma 1995; September 10-13: La Baule, France.
6. Björkstrand B. 474 autotransplants in multiple myeloma - results of the EBMT. Vth International Workshop on Multiple Myeloma 1995; September 10-13: La Baule, France.
7. Juliusson G, Liliemark J. Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance. Leuk Lymphoma 1994;13:75-80.
8. Estey EH, Kurzrock R, Kantarjian HM et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 1992;79:882-887.
9. Dimopoulos MA, Kantarjian HM, Estey EH et al. 2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood 1992;80:1626.
10. Niesvizky R, Siegel D, Michaeli J. 2-Chlorodeoxyadenosine for multiple myeloma. Blood 1993;81:868.
11. Hansen HH, Eisenhauer EA, Hansen M et al. New cytostatic drugs in ovarian cancer. Ann Oncol 1993;4(suppl 4):S63-S70.
12. Shepherd FA. Treatment of advanced non-small cell lung cancer. Semin Oncol 1994;21:7-18.
13. Villunger A, Egle A, Kos M et al. Constituents of an automne IL-6 loop in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies. Int J Cancer 1996;65:498-505.
14. Gruber J, Sgone R, Hu YH et al. Thymocyte apoptosis induced by elevated endogenous corticosterone levels. Eur J Immunol 1994;24:1115-1121.
15. Sgonc R, Boeck G, Dietrich H et al. Simultaneous determination of cell surface antigens and apoptosis. Trends Genet 1994;10:41-42.
16. Nicoletti I, Migliorati G, Pagliacci MC et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-279.
17. Grunewald R, Kantarjian H, Keating MJ et al. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 1990;50:6823-6826.
18. Grunewald R, Kantarjian H, Du M et al. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 1992;10:406-413.
19. Catimel G, Vermorken JB, Clavel M et al. A phase II study of gemcitabine (LY 18801 1) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994;5:543-547.
20. O'Rourke TJ, Brown TD, Havlin K et al. Phase I clinical trial of gemcitabine given as an intravenous bolus on five consecutive days (Letter). Eur J Cancer 1994;30A:417-418.
21. Carson DA, Wasson DB, Kaye J et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA 1980;77:6860-6865.
22. Cardinaud R. Nucleoside deoxyribosyltransferase from lactobacillus helveticus. Methods Enzymol 1978;51:440-446.
23. Iscove NN. The role of erythropoietin in regulation of population size and cell cycling of early and late erythroid precursors in mouse bone marrow. Cell Tissue Kinet 1977;10:320-323.
24. Boyum A. Separation of blood leukocytes, granulocytes and lymphocytes. Tiss Antigens 1974;4:260-269.
25. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-257.
26. Sgonc R, Wick G. Methods for the detection of apoptosis. Int Arch Allergy Immunol 1994;105:327-332.
27. Lund B, Kristjansen PE, Hansen HH. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 1993;19:45-55.
28. Chen YH, Feng XX, Schilder L. Effect of vincristine, adriamycin and glucocorticoids on myeloma cells in vitro. Acta Haematol 1993;89:61-69.
29. Braakhuis BJ, van Dongen GA, Vermorken JB et al. Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 1991;51:211-214.
30. Moore DF Jr, Pazdur R, Daugherty K et al. Phase II study of gemcitabine in advanced colorectal adenocarcinoma. Invest New Drugs 1992;10:323-325.
31. Lilenbaum RC, Green MR. Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol 1993;11:1391-1402.
32. Cohen JJ. Apoptosis. Immunol Today 1993;14:126-130.
33. Bouffard DY, Momparler LF, Momparler RL. Comparison of antineoplastic activity of 2′,2′-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells. Anticancer Drugs 1991;2:49-55.
34. Csoka K, Lilienmark J, Larrson R et al. Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol 1995;22(suppl 11):47-53.
35. Dimopoulos MA, Kantarjian H, Estey E et al. Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993;118:195-198.
36. Saven A, Piro LD. 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia and chronic lymphocytic leukemia. Leuk Lymphoma 1993;11(suppl 2):109-114.
37. Robertson LE, Chubb S, Meyn RE et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine. Blood 1993;81:143-150.
38. Santana VM, Mirro J Jr, Kearns C et al. 2-chlorodeoxyadenosine produces a high rate of complete hEmatologic remission in relapsed acute myeloid leukemia. J Clin Oncol 1992;10:364-370.
39. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992;340:952-956.
40. Bhalla K, Nayak R, Grant S. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-β-D-arabinofuranosylcytosine. Cancer Res 1984;44:5029-5037.
41. Ruiz van Haperen VWT, Veerman G, Erikson S et al. Development and characterization of AG6000: a gemcitabine (2′ 2′-difluorodeoxycytidine, dFdC) resistant human ovarian cancer cell line. Proc Am Assoc Cancer Res 1993;34:300-307.